RBBP4

Across TCGA pan-cancer cohorts, RBBP4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBBP4 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RBBP4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RBBP4 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where RBBP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.930	0.416	.005	12	view →
HNSC	DFS	Median	III,IV	0.906	1.000	.006	10	view →
CCRCC	DFS	Quartile	All	0.816	1.000	.009	8	view →
PDAC	DFS	Quartile	III,IV	0.299	0.600	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBBP4–LUAD (DFS)

Open the LUAD breakdown →